• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Would/What kind /of/ there/ be any side effects of CBD,L-theanine,serine compound mixture?

cbd neurocognition serine

  • Please log in to reply
1 reply to this topic

#1 Ruth

  • Guest
  • 114 posts
  • 13
  • Location:USA

Posted 16 December 2017 - 06:25 PM


Would this stabilize endocannabinodergic-dopaminergic-glutamatergic-serotoninergic systems?

Medium-high dose CBD(400mg-900mg)
L-theanine dose(1,000 milligrams)
d-serine(500mg)

Lurasidone(60-90mg)1-3x weekly


and tryptophan and tyrosine(.8g) and (1g)
and various other supplements and phyto- and nutritional- factors.

each day?

#2 Ruth

  • Topic Starter
  • Guest
  • 114 posts
  • 13
  • Location:USA

Posted 16 December 2017 - 10:24 PM

CBD: https://www.scienced...128007563000922 "Schizophrenia presents positive, negative, and cognitive symptoms. The available antipsychotic drugs treat mainly the positive symptoms, having a low therapeutic efficacy against the negative and cognitive symptoms. Furthermore, they induce important motor and metabolic side effects. Therefore, the search for new therapeutic strategies is crucial. Alterations in the endocannabinoid system seem to be implicated in the pathophysiology of schizophrenia. In this scenario, cannabidiol (CBD)—a nonpsychotomimetic compound of cannabis—emerges as a potential new therapeutic strategy for schizophrenia. This chapter reviews the available data regarding the antipsychotic effects of CBD. CBD seems able to treat the positive symptoms of schizophrenia, and represents an advance with regard to the existing antipsychotics, since it might also be effective against the negative and cognitive symptoms. Moreover, significant side effects are not seen with cannabidiol treatment. However, despite the auspicious evidence, further clinical and preclinical studies are still necessary to strengthen CBD’s antipsychotic profile."

Ascorbic acid: http://www.sciencedi...024320579900912 "Ascorbic acid, at concentrations below that normally present in the brain, inhibited the dopamine-sensitive adenylate cyclase
in

vitro
. Ascorbate had no effect on the norepinephrine-sensitive adenylate cyclase. To study the
in

vivo
effect of ascorbic acid on central dopaminergic systems, mice (C57 B1/6J) were injected with pharmacological doses (2 g/kg) of ascorbate, which produced a significant elevation in brain ascorbate concentration. Injecting the mice with ascorbate (2 g/kg) blocked the amphetamine-induced (15 mg/kg) increase in stereotype behavior which has been reported to be mediated by dopaminergic neural systems. Ascorbate had no effect on the amphetamine-induced locomotor activity thought to be mediated by norepinephrine systems. Ascorbate (1 g/kg) attenuated apmorphine-induced hypothermia in this same strain of mice. This demonstrates the specific neurochemical, physiological, and behavioral alterations in dopaminergic systems produced by ascorbic acid and suggests possible therapeutic uses for ascorbate in conditions involving functional dopamine excess."

CDP: https://link.springe...3-319-57505-6_3 "Choline, the precursor of acetylcholine (ACh), is an essential amino acid that is associated with healthy brain development and neuroprotective functions. Choline supplementation can enhance ACh in the brain, which is important for learning and memory functions. Several studies investigated the cognitive enhancing effects of choline in animal models. However, reports on the effectiveness of choline supplementation in healthy humans vary considerably, with some studies showing positive effects, whereas others report no significant changes. In this chapter, we review the available cognitive and behavioral studies on choline, to clarify if and under which conditions choline supplementation might enhance cognition in heathy humans. A long-term diet rich in choline seems to enhance cognitive functioning across the life span. Short-term choline supplementation seems to have the potential to enhance various cognitive processes, especially in poor performers. Although more research is needed to fully understand the effects choline exerts on cognition, we conclude that choline is a promising tool for enhancing in particular memory functions in low-performing individuals.


L-theanine: https://raypeatforum...symptoms.11513/ "Add-on Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-week, randomized, double... - PubMed - NCBI

Abstract
AIMS:
Pregnenolone (PREG) and L-Theanine (LT) have shown ameliorative effects on various schizophrenia symptoms. This is the first study to evaluate the efficacy and safety of augmentation of antipsychotic treatment among patients with chronic schizophrenia or schizoaffective disorder with PREG - LT.

METHODS:
Double-blind, placebo-controlled trial of PREG - LT or placebo augmentation was conducted for 8 weeks with 40 chronic DSM-IV schizophrenia and schizoaffective disorder patients with suboptimal response to antipsychotics. Oral PREG (50 mg/day) with LT (400 mg/day) or placebo were added to a stable regimen of antipsychotic medication from March 2011 to October 2013. The participants were rated using the Scale for the Assessment of Negative Symptoms (SANS), Hamilton Scale for Anxiety (HAM-A), and Positive and Negative Syndrome Scale (PANSS) scales bi-weekly. The decrease of SANS and HAM-A scores were the co-primary outcomes. Secondary outcomes included assessments of general functioning and side effects.

RESULTS:
Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved, with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group. Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF). Positive symptoms, antipsychotic agents, concomitant drugs, and illness duration did not associate significantly with effect of PREG-LT augmentation. PREG-LT was well-tolerated.

CONCLUSIONS:
Pregnenolone with L-Theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder. Further studies are warranted.


d-serine: https://www.scienced...006322398002790 Background: Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has been implicated in the pathophysiology of schizophrenia. D-serine is a full agonist of the glycine site of NMDA receptor, an endogenous cotransmitter enriched in corticolimbic regions and distributed in parallel with NMDA receptor. Supplementation of D-serine may improve the symptoms of schizophrenia.

Methods: Thirty-one Taiwanese schizophrenic patients enrolled in a 6-week double-blind, placebo-controlled trial of D-serine (30 mg/kg/day), which was added to their stable antipsychotic regimens. Of these, 28 completed the trial. Measures of clinical efficacy, side effects, and serum levels of amino acids and D-serine were determined every other week. Wisconsin Card Sorting Test (WCST) was performed at the beginning and end of the trial.

Results: Patients who received D-serine treatment revealed significant improvements in their positive, negative, and cognitive symptoms as well as some performance in WCST. D-serine levels at week 4 and 6 significantly predicted the improvements. D-serine was well tolerated and no significant side effects were noted.

Conclusions: The significant improvement with the D-serine further supports the hypothesis of NMDA receptor hypofunction in schizophrenia. Given the effects of D-serine on positive symptoms, a trial of D-serine alone in schizophrenia should be considered.


Nicotine: "Objective: Research on the impact of nicotine on schizophrenia and antipsychotic medications was reviewed to determine ways to improve treatment planning for patients with schizophrenia who smoke and to evaluate smoking cessation programs for this population. Methods: All major research databases were searched. The review focuses on reports published since 1990. Results: Smoking improves processing of auditory stimuli (sensory gating) by patients with schizophrenia and may lessen negative symptoms by increasing dopamine in the nucleus accumbens and the prefrontal and frontal cortex. Use of traditional antipsychotics may result in patients’ smoking more, whereas patients taking atypical antipsychotics may smoke less. Patients who smoke metabolize antipsychotics faster than nonsmoking patients. Smoking cessation programs for outpatients with schizophrenia report a success rate of about 12 percent after six months. No studies of cessation programs for chronically ill inpatients with schizophrenia have been published. Several hospitals have implemented smoking bans with equivocal results. Conclusions: Nicotine affects both schizophrenia and antipsychotic medications. Neurobiological and psychosocial factors reinforce the high use of nicotine by patients with schizophrenia"

https://www.research...nscious_Monkeys

The effects of acute nicotine were determined on dopamine (DA) D(1) (D(1)R) and D(2) (D(2)R) receptor binding in the neocortex of conscious monkeys under control conditions as well as after chronic pretreatment with MK-801 (dizocilpine), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Extrastriatal neocortical D(1)R and D(2)R binding was evaluated with [(11)C]NNC112 and [(11)C]FLB457 with high-specific radioactivity using positron emission tomography (PET). Acute administration of nicotine bitartrate, given as an intravenous (i.v.) bolus plus infusion for 30 min at doses of 32 microg/kg+0.8 microg/kg/min or 100 microg/kg+2.53 microg/kg/min as base, induced slight but significant dose-dependent increases of DA in the extracellular fluid of prefrontal cortex (PFC) as determined by microdialysis. However, acute nicotine did not affect either [(11)C]NNC112 or [(11)C]FLB457 binding to D(1)R or D(2)R, respectively, in any cortical region. Chronic MK-801 (0.03 mg/kg, intramuscularly (i.m.), twice daily for 13 days) increased [(11)C]NNC112 binding to D(1)R in PFC. No significant changes were detected in [(11)C]FLB457 binding to PFC D(2)R. Although chronic MK-801 lowered baseline DA and glutamate levels in PFC, acute nicotine normalized reduced DA to control levels. Acute nicotine dose-dependently normalized the increased binding of [(11)C]NNC112 to D(1)R produced by chronic MK-801 but [(11)C]FLB457 binding to PFC D(2)R did not change. Working memory performance, impaired after chronic MK-801, was partially improved by acute nicotine. These results demonstrate that acute nicotine normalizes MK-801-induced PFC abnormality of D(1)R in PFC.

Nicotine Normalizes Increased Prefrontal Cortical Dopamine D1 Receptor Binding and Decreased Working Memory Performance Produced by Repeated Pretreatment with MK-801: A PET Study in Conscious Monkeys (PDF Download Available). Available from: https://www.research...nscious_Monkeys [accessed Dec 16 2017].


Diet: http://www.tandfonli...rnalCode=ynns20 "PREvención con Dieta MEDiterránea (PREDIMED) is a randomized clinical trial designed to assess the effect of a Mediterranean diet (MeDiet) on the primary prevention of cardiovascular disease. For this analysis, 243 participants from the Navarra centre were randomly selected. Participants were assigned to one of three dietary interventions: control (low-fat) diet, MeDiet supplemented with virgin olive oil (MeDiet + VOO), or MeDiet supplemented with nuts (MeDiet + Nuts). Plasma BDNF levels were measured after 3 years of intervention. Multivariate-adjusted means of BDNF for each intervention were compared using generalized linear models. Logistic regression models were fit to assess the association between the dietary intervention and the likelihood to have low plasma BDNF values (<13 µg/ml, 10th percentile). Analyses were repeated after stratifying the sample according to baseline prevalence of different diseases.

Results

Higher but non-significant plasma BDNF levels were observed for participants assigned to both MeDiets. Participants assigned to MeDiet + Nuts showed a significant lower risk (odds ratios (OR) = 0.22; 95% confidence intervals (CI) = 0.05–0.90) of low plasma BDNF values (<13 µg/ml) as compared to the control group. Among participants with prevalent depression at baseline, significantly higher BDNF levels were found for those assigned to the MeDiet.


(Endo)-cannabinoids: https://www.medscape...warticle/860664 MADRID — Psychosis patients who have used cannabis have greater premorbid social skills than patients with psychosis who have never used the drug, data from five European countries suggest.

Laura Ferraro, a PhD student in psychiatry at the University of Palermo, in Italy, and colleagues found that lifetime cannabis use was associated with significantly increased improvements in premorbid social adjustment among psychosis patients.


Moreover, the results, which were presented here at the European Psychiatric Association (EPA) 24th ​Congress, indicate that the impact of cannabis on sociability was significantly greater among psychosis patients than among healthy individuals.

Moreover, a previous study by Ferraro and colleagues showed that among patients with first-episode psychosis (FEP), those who used cannabis had a higher IQ.


https://www.leafscie...-schizophrenia/ With the current state of research, it is generally considered safer to:
◾ Wait until after adolescence (18-25 years old) before using marijuana
◾Use marijuana in small doses and don’t consume too much at once
◾Pick strains that are lower in THC, and higher in CBD





https://www.medscape...stract/27939135 "Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation.

Eur Neuropsychopharmacol. 2016; (ISSN: 1873-7862)

Luoni A; Richetto J; Longo L; Riva MA


Prenatal maternal infection represents a risk factor for the development of psychopathologic conditions later in life. Clinical evidence is also supported by animal models in which the vulnerability to develop a schizophrenic-like phenotype likely originates from inflammatory processes as early as in the womb. Prenatal immune challenge, for example, induces a variety of long-term behavioral alterations in mice, such as deficits in recognition and spatial working memory, perseverative behaviors and social impairments, which are relevant to different symptom clusters of schizophrenia. Here, we investigated the modulation of GABAergic markers in the dorsal and ventral hippocampus of adult mice exposed to late prenatal immune challenge with the viral mimetic Poly(I:C) (polyriboinosinic-polyribocytidilic-acid) at gestational day 17, and we evaluated the ability of chronic treatment with the multi-receptor antipsychotic lurasidone to modulate the alterations produced by maternal infection. Poly(I:C) mice show a significant reduction of key GABAergic markers, such as GAD67 and parvalbumin, specifically in the dorsal hippocampus, which were normalized by chronic lurasidone administration. Moreover, chronic drug administration increases the expression of the pool of brain derived neurotrophic factor (BDNF) transcripts with the long 3'-UTR as well as the levels of mature BDNF protein in the synaptosomal compartment, selectively in dorsal hippocampus. All in all, our findings demonstrate that lurasidone is effective in ameliorating molecular abnormalities observed in Poly(I:C) mice, providing further support to the neuroplastic properties of this multi-receptor antipsychotic drug.
"

Edited by Ruth, 16 December 2017 - 10:30 PM.


sponsored ad

  • Advert
Advertisements help to support the work of this non-profit organisation. To go ad-free join as a Member.




Also tagged with one or more of these keywords: cbd, neurocognition, serine

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users